Can a pill tackle Tough-to-Treat leukemia?
Disease control
Recruiting now
This study tests an experimental oral medicine called CHM-029 in adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments, and that carries specific genetic changes (NPM1 mutations or KMT2A/NUP98 rearrangements). The main goals are to fin…
Phase: PHASE1 • Sponsor: Charm Therapeutics • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC